Article List
List all articles in the database by earliest discovery_date
GET /articles/?format=api&page=2444
{ "count": 24680, "next": "http://api.gregory-ms.com/articles/?format=api&page=2445", "previous": "http://api.gregory-ms.com/articles/?format=api&page=2443", "results": [ { "article_id": 249, "title": "Renal transplantation outcomes in obese patients: a French cohort-based study", "summary": "Background: Whilst there are a number of publications comparing the relationship between body mass index (BMI) of kidney transplant recipients and graft/patient survival, no study has assessed this for a French patient cohort.MethodsIn this study, cause-specific Cox models were used to study patient and graft survival and several other time-to-event measures. Logistic regressions were performed to study surgical complications at 30 days post-transplantation as well as delayed graft function.ResultsAmong the 4691 included patients, 747 patients were considered obese with a BMI level greater than 30 kg/m2. We observed a higher mortality for obese recipients (HR = 1.37, p = 0.0086) and higher risks of serious bacterial infections (HR = 1.24, p = 0.0006) and cardiac complications (HR = 1.45, p < 0.0001). We observed a trend towards death censored graft survival (HR = 1.22, p = 0.0666) and no significant increased risk of early surgical complications.ConclusionsWe showed that obesity increased the risk of death and serious bacterial infections and cardiac complications in obese French kidney transplant recipients. Further epidemiologic studies aiming to compare obese recipients versus obese candidates remaining on dialysis are needed to improve the guidelines for obese patient transplant allocation.", "link": "https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-021-02278-1", "published_date": "2021-03-05T00:00:00Z", "sources": [ "BioMedCentral" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "BMC Nephrology", "authors": [ { "author_id": 161361, "given_name": "Y.", "family_name": "Foucher", "ORCID": "http://orcid.org/0000-0003-0330-7457", "country": "FR" }, { "author_id": 241649, "given_name": "M.", "family_name": "Lorent", "ORCID": null, "country": null }, { "author_id": 241650, "given_name": "L.", "family_name": "Albano", "ORCID": null, "country": null }, { "author_id": 241651, "given_name": "S.", "family_name": "Roux", "ORCID": null, "country": null }, { "author_id": 241652, "given_name": "V.", "family_name": "Pernin", "ORCID": null, "country": null }, { "author_id": 241653, "given_name": "M.", "family_name": "Le Quintrec", "ORCID": null, "country": null }, { "author_id": 241654, "given_name": "C.", "family_name": "Legendre", "ORCID": null, "country": null }, { "author_id": 241655, "given_name": "F.", "family_name": "Buron", "ORCID": null, "country": null }, { "author_id": 241656, "given_name": "E.", "family_name": "Morelon", "ORCID": null, "country": null }, { "author_id": 241657, "given_name": "S.", "family_name": "Girerd", "ORCID": null, "country": null }, { "author_id": 241658, "given_name": "M.", "family_name": "Ladrière", "ORCID": null, "country": null }, { "author_id": 241659, "given_name": "D.", "family_name": "Glotz", "ORCID": null, "country": null }, { "author_id": 241661, "given_name": "C.", "family_name": "Lefaucher", "ORCID": null, "country": null }, { "author_id": 241663, "given_name": "C.", "family_name": "Kerleau", "ORCID": null, "country": null }, { "author_id": 241664, "given_name": "J.", "family_name": "Dantal", "ORCID": null, "country": null }, { "author_id": 241666, "given_name": "J.", "family_name": "Branchereau", "ORCID": null, "country": null }, { "author_id": 241668, "given_name": "M.", "family_name": "Giral", "ORCID": null, "country": null } ], "relevant": false, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-06T10:18:23Z", "noun_phrases": [ "Renal transplantation outcomes", "obese patients", "a French cohort-based study" ], "doi": "10.1186/s12882-021-02278-1", "access": "open", "takeaways": " Obesity increased the risk of death and serious bacterial infections and cardiac complications in obese French kidney transplant recipients . Further epidemiologic studies aiming to compare obese recipients versus obese candidates remaining on dialysis are needed to improve the guidelines for obese patient transplant allocation .", "categories": [] }, { "article_id": 251, "title": "Eye Movement Desensitization (EMD) to reduce posttraumatic stress disorder-related stress reactivity in Indonesia PTSD patients: a study protocol for a randomized controlled trial", "summary": "Background: Posttraumatic stress disorder (PTSD) may develop after exposure to a traumatic event. Eye Movement Desensitization and Reprocessing (EMDR) is an evidence-based psychological treatment for PTSD. It is yet unclear whether eye movements also reduce stress reactivity in PTSD patients. This study aims to test whether eye movements, as provided during Eye Movement Desensitization (EMD), are more effective in reducing stress reactivity in PTSD patients as compared to a retrieval-only control condition.MethodsThe study includes participants who meet criteria of PTSD of the public psychological services in Jakarta and Bandung, Indonesia. One hundred and ten participants are randomly assigned to either an (1) Eye Movement Desensitization group (n = 55) or (2) retrieval-only control group (n = 55). Participants are assessed at baseline (T0), post-treatment (T1), 1 month (T2), and at 3 months follow-up (T3). Participants are exposed to a script-driven imagery procedure at T0 and T1. The primary outcome is heart rate variability (HRV) stress reactivity during script-driven imagery. Secondary outcomes include heart rate (HR), pre-ejection period (PEP), saliva cortisol levels, PTSD symptoms, neurocognitive functioning, symptoms of anxiety and depression, perceived stress level, and quality of life.DiscussionIf the EMD intervention is effective in reducing stress reactivity outcomes, this would give us more insight into the underlying mechanisms of EMDR’s effectiveness in PTSD symptom reduction.Trial registrationISRCTN registry ISRCTN55239132. Registered on 19 December 2017.", "link": "https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-021-05100-3", "published_date": "2021-03-04T00:00:00Z", "sources": [ "BioMedCentral" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "Trials", "authors": [ { "author_id": 198258, "given_name": "Eka", "family_name": "Susanty", "ORCID": "http://orcid.org/0000-0002-8725-143X", "country": null }, { "author_id": 294310, "given_name": "Marit", "family_name": "Sijbrandij", "ORCID": null, "country": null }, { "author_id": 294312, "given_name": "Wilis", "family_name": "Srisayekti", "ORCID": null, "country": null }, { "author_id": 294313, "given_name": "Anja C.", "family_name": "Huizink", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-06T10:18:23Z", "noun_phrases": [ "Eye Movement Desensitization", "EMD", "posttraumatic stress disorder-related stress reactivity", "Indonesia", "patients", "a study protocol", "a randomized controlled trial" ], "doi": "10.1186/s13063-021-05100-3", "access": "open", "takeaways": " Eye Movement Desensitization and Reprocessing is an evidence-based psychological treatment for PTSD . It is yet unclear whether eye movements also reduce stress reactivity in PTSD patients .", "categories": [] }, { "article_id": 248, "title": "The involvement of NLRP3 inflammasome in the treatment of neurodegenerative diseases", "summary": "<div><p>Biomed Pharmacother. 2021 Mar 2;138:111428. doi: 10.1016/j.biopha.2021.111428. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">In an ageing society, neurodegenerative diseases have attracted attention because of their high incidence worldwide. Despite extensive research, there is a lack of conclusive insights into the pathogenesis of neurodegenerative diseases, which limit the strategies for symptomatic treatment. Therefore, better elucidation of the molecular mechanisms involved in neurodegenerative diseases can provide an important theoretical basis for the discovery of new and effective prevention and treatment methods. The innate immune system is activated during the ageing process and in response to neurodegenerative diseases. Inflammasomes are multiprotein complexes that play an important role in the activation of the innate immune system. They mediate inflammatory reactions and pyroptosis, which are closely involved in neurodegeneration. There are different types of inflammasomes, although the nucleotide-binding oligomerization domain-like receptor pyrin domain-containing 3 (NLRP3) inflammasome is the most common inflammasome; NLRP3 plays an important role in the pathogenesis of neurodegenerative diseases. In this review, we will discuss the mechanisms that are involved in the activation of the NLRP3 inflammasome and its crucial role in the pathology of neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and multiple sclerosis. We will also review various treatments that target the NLRP3 inflammasome pathway and alleviate neuroinflammation. Finally, we will summarize the novel treatment strategies for neurodegenerative disorders.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33667787/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210306051644&v=2.14.2\">33667787</a> | DOI:<a href=\"https://doi.org/10.1016/j.biopha.2021.111428\">10.1016/j.biopha.2021.111428</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33667787/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-06T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Elsevier BV", "container_title": "Biomedicine & Pharmacotherapy", "authors": [ { "author_id": 241073, "given_name": "Ya-Shuo", "family_name": "Feng", "ORCID": null, "country": null }, { "author_id": 241075, "given_name": "Zi-Xuan", "family_name": "Tan", "ORCID": null, "country": null }, { "author_id": 241077, "given_name": "Lin-Yu", "family_name": "Wu", "ORCID": null, "country": null }, { "author_id": 241079, "given_name": "Fang", "family_name": "Dong", "ORCID": null, "country": null }, { "author_id": 195877, "given_name": "Feng", "family_name": "Zhang", "ORCID": "http://orcid.org/0000-0003-1339-5956", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-06T10:16:45Z", "noun_phrases": [ "The involvement", "NLRP3 inflammasome", "the treatment", "neurodegenerative diseases" ], "doi": "10.1016/j.biopha.2021.111428", "access": "open", "takeaways": " Inflammasomes are multiprotein complexes that play an important role in the activation of the innate immune system . They mediate inflammatory reactions and pyroptosis, which are closely involved in neurodegeneration . NLRP3 inflammasome plays a crucial role in pathology of Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis .", "categories": [] }, { "article_id": 246, "title": "Safety of S1P Modulators in Patients with Immune-Mediated Diseases: A Systematic Review and Meta-Analysis", "summary": "<div><p>Drug Saf. 2021 Mar 5. doi: 10.1007/s40264-021-01057-z. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">INTRODUCTION: Sphingosine-1-phosphate modulators are approved for the treatment of multiple sclerosis and are under development for other immune-mediated conditions; however, safety concerns have arisen.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">OBJECTIVE: The objective of this systematic review was to investigate the safety profile of S1P modulators in patients with multiple sclerosis, ulcerative colitis, Crohn's disease, psoriasis, and systemic lupus erythematosus.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: We searched MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials from 1 January, 1990 through 1 April, 2020. We also performed a manual review of conference databases from 2017 through 2020. The primary outcome was the occurrence of adverse events and serious adverse events. We also estimated the occurrence of serious infections, herpes zoster infection, malignancy, bradycardia, atrio-ventricular block, and macular edema. We performed a meta-analysis of controlled studies to assess the risks of such events.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: We identified 3843 citations; of these, 26 studies were finally included, comprising 9604 patients who were exposed to a sphingosine-1-phosphate modulator. A meta-analysis of randomized controlled trials showed an increased risk in herpes zoster infection [risk ratio, 1.75 (95% confidence interval 1.09-2.80)], bradycardia [2.64 (1.77-3.96)], and atrio-ventricular block [1.73 (1.03-2.91)] among subjects exposed to sphingosine-1-phosphate modulators as compared with a placebo or an active comparator.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSIONS: We found an increased risk of herpes zoster infection, and transient cardiovascular events among patients treated with sphingosine-1-phosphate modulators.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CLINICAL TRIAL REGISTRATION: PROSPERO CRD42020172575.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33666900/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210305195644&v=2.14.2\">33666900</a> | DOI:<a href=\"https://doi.org/10.1007/s40264-021-01057-z\">10.1007/s40264-021-01057-z</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33666900/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-06T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "Drug Safety", "authors": [ { "author_id": 296973, "given_name": "Juan S.", "family_name": "Lasa", "ORCID": null, "country": null }, { "author_id": 296974, "given_name": "Pablo A.", "family_name": "Olivera", "ORCID": null, "country": null }, { "author_id": 296975, "given_name": "Stefanos", "family_name": "Bonovas", "ORCID": null, "country": null }, { "author_id": 281139, "given_name": "Silvio", "family_name": "Danese", "ORCID": null, "country": null }, { "author_id": 296976, "given_name": "Laurent", "family_name": "Peyrin-Biroulet", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-06T00:56:45Z", "noun_phrases": [ "Safety", "S1P Modulators", "Patients", "Immune-Mediated Diseases", "A Systematic Review", "Meta-Analysis" ], "doi": "10.1007/s40264-021-01057-z", "access": "restricted", "takeaways": " Sphingosine-1-phosphate modulators are approved for the treatment of multiple sclerosis and are under development for other immune-mediated conditions . We found an increased risk of herpes zoster infection, bradycardia, atrio-ventricular block, and transient cardiovascular events .", "categories": [] }, { "article_id": 247, "title": "Illuminating the in vitro effects of Epstein-Barr virus and vitamin D on immune response in multiple sclerosis patients", "summary": "<div><p>J Neurovirol. 2021 Mar 5. doi: 10.1007/s13365-021-00951-7. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">Given the complexity of immune complex diseases including multiple sclerosis (MS) and the plausible interactions between different risk factors, delineating the interplay between them would be imperative. The current study aimed to evaluate the in vitro effects of Epstein-Barr virus (EBV) and vitamin D on immune response in MS patients and healthy controls. The status of vitamin D and EBV load was evaluated using multiple techniques. In vitro EBV-infected peripheral blood mononuclear cells (PBMCs), in the presence or absence of vitamin D, were checked for IL-10, IFN-γ, and vitamin D receptor. MS patients showed significantly higher plasma levels of 1,25-(OH)2D but not 25-OHD, increased EBV load, and lower levels of vitamin D receptor (VDR) expression compared with healthy controls. Interestingly, an inverse correlation was observed between VDR expression and EBV load in PBMCs. Indeed, the levels of IFN-γ and IL-10 production were significantly higher in supernatant collected from in vitro EBV-infected PBMCs in MS patients compared with controls. While all vitamin D-treated PBMCs showed reduced levels of IFN-γ production, in vitro treatment of vitamin D showed no influence in IL-10 production. EBV and vitamin D were found to exert opposite in vitro effects on immune dysregulation in these patients. Our results highlight the complex interactions of different risk factors with immune system.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33666884/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210305195644&v=2.14.2\">33666884</a> | DOI:<a href=\"https://doi.org/10.1007/s13365-021-00951-7\">10.1007/s13365-021-00951-7</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33666884/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-04T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "Journal of NeuroVirology", "authors": [ { "author_id": 241041, "given_name": "Majid", "family_name": "Teymoori-Rad", "ORCID": null, "country": null }, { "author_id": 184389, "given_name": "Mohammad Ali", "family_name": "Sahraian", "ORCID": "http://orcid.org/0000-0002-3224-8807", "country": null }, { "author_id": 241042, "given_name": "Talat", "family_name": "Mokhtariazad", "ORCID": null, "country": null }, { "author_id": 241043, "given_name": "Ahmad", "family_name": "Nejati", "ORCID": null, "country": null }, { "author_id": 241045, "given_name": "Razieh Sadat Kazemi", "family_name": "Mozdabadi", "ORCID": null, "country": null }, { "author_id": 241047, "given_name": "Mohammad Mehdi", "family_name": "Amiri", "ORCID": null, "country": null }, { "author_id": 241049, "given_name": "Fazel", "family_name": "Shokri", "ORCID": null, "country": null }, { "author_id": 165640, "given_name": "Sayed Mahdi", "family_name": "Marashi", "ORCID": "http://orcid.org/0000-0001-7754-2674", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-06T00:56:45Z", "noun_phrases": [ "the in vitro effects", "Epstein-Barr virus", "vitamin D", "immune response", "multiple sclerosis patients" ], "doi": "10.1007/s13365-021-00951-7", "access": "restricted", "takeaways": " MS patients showed significantly higher plasma levels of 1,25-(OH)2D but not 25-OHD, increased EBV load, and lower levels of vitamin D receptor (VDR) expression .", "categories": [ { "category_id": 46, "category_description": "Epstein-Barr virus (EBV), also known as human herpesvirus 4, is a member of the herpes virus family. It is one of the most common human viruses. EBV is found all over the world. Most people get infected with EBV at some point in their lives. EBV spreads most commonly through bodily fluids, primarily saliva. EBV can cause infectious mononucleosis, also called mono, and other illnesses.\r\n\r\nsource: <a href=\"https://www.cdc.gov/epstein-barr/about-ebv.html\">https://www.cdc.gov/epstein-barr/about-ebv.html</a>\r\n\r\nEBV may be a leading cause of multiple sclerosis. \r\nsource: <a href=\"https://www.nature.com/articles/s41582-023-00775-5\">https://www.nature.com/articles/s41582-023-00775-5</a>", "category_name": "Epstein-Barr Virus", "category_slug": "epstein-barr-virus", "category_terms": [ "ebv", "Epstein-Barr" ], "article_count": 163 } ] }, { "article_id": 239, "title": "Functional Reach Test for Multiple Sclerosis (MS)", "summary": "Functional Reach Test for Multiple Sclerosis (MS)", "link": "https://www.apta.org/patient-care/evidence-based-practice-resources/test-measures/functional-reach-test-for-multiple-sclerosis-ms", "published_date": "2021-12-29T18:48:03Z", "sources": [ "APTA" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Knowledge E DMCC", "container_title": "Current Journal of Neurology", "authors": [], "relevant": false, "ml_prediction_gnb": true, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-05T23:50:03Z", "noun_phrases": [ "Functional Reach Test", "Multiple Sclerosis", "MS" ], "doi": null, "access": "unknown", "takeaways": "", "categories": [] }, { "article_id": 241, "title": "Multiple Sclerosis (MS) Quality of Life Inventory", "summary": "Measures fatigue, pain, gait, quality of life, role function, social function.", "link": "https://www.apta.org/patient-care/evidence-based-practice-resources/test-measures/multiple-sclerosis-ms-quality-of-life-inventory-", "published_date": "2021-12-29T18:47:56Z", "sources": [ "APTA" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": null, "container_title": null, "authors": [], "relevant": false, "ml_prediction_gnb": true, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-05T23:50:03Z", "noun_phrases": [ "Life" ], "doi": null, "access": "unknown", "takeaways": "", "categories": [] }, { "article_id": 238, "title": "Activities-specific Balance Confidence (ABC) Scale for Multiple Sclerosis (MS) ", "summary": "A 16-item self-report measure in which patients rate their balance confidence in performing several activities.", "link": "https://www.apta.org/patient-care/evidence-based-practice-resources/test-measures/activities-specific-balance-confidence-abc-scale-for-multiple-sclerosis-ms", "published_date": "2021-12-29T18:48:05.846000Z", "sources": [ "APTA" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "BMJ", "container_title": "Journal of Neurology, Neurosurgery & Psychiatry", "authors": [], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-05T23:50:03Z", "noun_phrases": [ "Activities-specific Balance Confidence (ABC) Scale", "Multiple Sclerosis", "MS" ], "doi": null, "access": "unknown", "takeaways": "", "categories": [] }, { "article_id": 237, "title": "Four Square Step Test (FSST) for Multiple Sclerosis (MS)", "summary": "Four Square Step Test (FSST) for Multiple Sclerosis (MS)", "link": "https://www.apta.org/patient-care/evidence-based-practice-resources/test-measures/four-square-step-test-fsst-for-multiple-sclerosis-ms", "published_date": "2021-12-29T18:48:07.583000Z", "sources": [ "APTA" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Elsevier BV", "container_title": "Archives of Medical Research", "authors": [], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-05T23:50:03Z", "noun_phrases": [ "Four Square Step Test", "FSST", "Multiple Sclerosis", "MS" ], "doi": null, "access": "unknown", "takeaways": "", "categories": [] }, { "article_id": 244, "title": "Multiple Sclerosis (MS) Functional Composite (MSFC) ", "summary": "Measures limitations and unidimensionality of prior existing functional status outcomes such as the Expanded Disability Status Scale (EDSS).", "link": "https://www.apta.org/patient-care/evidence-based-practice-resources/test-measures/multiple-sclerosis-ms-functional-composite-msfc-", "published_date": "2021-12-29T18:47:16.642000Z", "sources": [ "APTA" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-05T23:50:03Z", "noun_phrases": [ "Multiple Sclerosis (MS) Functional Composite", "MSFC" ], "doi": null, "access": "unknown", "takeaways": "", "categories": [] } ] }